Keyphrases
Israel
79%
Carbapenem-resistant Acinetobacter Baumannii
75%
Colistin
67%
Bloodstream Infection
47%
Escherichia Coli
29%
COVID-19
26%
Multidrug-resistant Gram-negative Bacteria
24%
Bacteremia
24%
Combination Therapy
23%
Randomized Controlled Trial
22%
Retrospective Cohort Study
21%
Monotherapy
20%
Israeli
20%
Severe Infection
20%
Meropenem
20%
Confidence Interval
19%
Carbapenemase-producing Enterobacterales
19%
Acinetobacter Baumannii (A. baumannii)
18%
Colorectal Surgery
18%
Carbapenem-resistant Enterobacterales
16%
Antimicrobial Resistance
16%
Healthcare Workers
16%
Colistin-meropenem
16%
Carbapenem Resistance
15%
Carbapenemase
14%
Clinical Failure
14%
Carbapenem-resistant Gram-negative Infections
14%
14-day Mortality
14%
Carbapenemases
14%
Murine Model
13%
Hospitalized Patients
13%
Population-based Study
13%
30-day Mortality
12%
Hospital-onset
12%
National Cohort Study
12%
Case Fatality Rate
12%
Surgical Site Infection
12%
Human Adenovirus Type 55
12%
Human Infection
12%
ESBL-PE
12%
In Vivo Fitness
12%
Ertapenem
12%
Enterobacterales
12%
Clinical Outcomes
11%
Sentinel
11%
Colistin-resistant
11%
Acute Hospital
10%
Intensive Care Unit
10%
Blood Culture
9%
Ceftazidime-avibactam
9%
Pharmacology, Toxicology and Pharmaceutical Science
Carbapenem
100%
Bloodstream Infection
72%
Colistimethate
64%
Infection
56%
Acinetobacter Baumannii
55%
Escherichia coli
29%
Meropenem
28%
Gram Negative Bacterium
23%
Infectious Agent
21%
Randomized Controlled Trial
20%
Carbapenemase
19%
Combination Therapy
16%
Diseases
15%
Antimicrobial Resistance
15%
Gram Negative Infection
14%
Monotherapy
13%
Antiinfective Agent
13%
Surgical Infection
12%
Cohort Study
12%
Prospective Study
12%
Ertapenem
12%
Asthma
12%
Antibiotics
11%
Extended Spectrum Beta Lactamase
10%
Staphylococcus Aureus
9%
Acinetobacter Infection
8%
Randomized Clinical Trial
8%
Inflammation
8%
Third Generation Cephalosporin
7%
Antibiotic Therapy
7%
Klebsiella pneumoniae
7%
Metronidazole
7%
Enterobacteriaceae
7%
Biological Marker
7%
Penicillinase
7%
Pharmacokinetics
6%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
6%
Bacterial Infection
6%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
6%
Synergism
6%
Prevalence
6%
Meningitis
6%
Prospective Cohort Study
6%
Avibactam Plus Ceftazidime
6%
Case-Control Study
6%
Placebo
6%
Syndrome
6%
Therapeutic Drug Monitoring
6%
Beta Lactamase Inhibitor
6%
Chronic Bronchitis
6%
Medicine and Dentistry
Carbapenem
82%
Infection
58%
Acinetobacter Baumannii
47%
Bloodstream Infection
45%
Colistimethate
42%
Gram-Negative Bacteria
23%
Meropenem
22%
Retrospective Cohort Study
21%
Carbapenemase
20%
Randomized Controlled Trial
20%
Escherichia coli
19%
Colorectal Surgery
18%
COVID-19
18%
Combination Therapy
16%
Antibiotic Therapy
15%
Beta-Lactamase
15%
Pathogen
14%
Surgical Infection
13%
Antiinfective Agent
13%
Monotherapy
13%
Antibiotic Resistance
12%
Prospective Study
12%
Ertapenem
12%
Adenoviridae
12%
Antibiotics
11%
Extended Spectrum Beta Lactamase
10%
Odds Ratio
10%
Intensive Care Unit
9%
Gram-Negative Bacterial Infection
9%
Diseases
8%
SOFA Score
8%
Acinetobacter Infection
8%
Randomized Clinical Trial
8%
Avibactam Plus Ceftazidime
8%
Third Generation Cephalosporin
7%
Colectomy
7%
Klebsiella pneumoniae
7%
Metronidazole
7%
Biological Marker
7%
Health Care Cost
7%
Staphylococcus Aureus
7%
Penicillinase
6%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
6%
Bacterial Infection
6%
Logistic Regression Analysis
6%
Antibiotic Prophylaxis
6%
Blood Culture
6%
Therapeutic Drug Monitoring
6%
Systematic Review
6%
PARP Inhibitor
6%